HIND Stock Analysis: Buy, Sell, or Hold?
HIND - Vyome Holdings, Inc. Common Stock
$2.17
0.05 (2.36%)
▲
5d:
+8.25%
30d:
-5.87%
90d:
+10.46%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Get Alerted When HIND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HIND shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: HIND shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: HIND is currently trading at $2.17, which is considered fair relative to its 30-day fair value range of $2.07 to $2.24.
Technical Outlook: Technically, HIND is showing sideways momentum. The price is approaching resistance at $2.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.50 (+431.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HIND is showing sideways momentum. The price is approaching resistance at $2.20. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.50 (+431.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.07 -
$2.24
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 431.2% below Wall St target ($11.50)
Trading Range Analysis
30-Day Trading Range
$2.07 -
$2.24
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.97
Resistance Level
$2.20
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.37
Wall Street Target
$11.50
(+431.2%)
Revenue Growth (YoY)
-84.1%
Share & Embed Analysis
Last updated: August 04, 2026 8:46 AM ET
Data refreshes hourly during market hours. Next update: 9:46 AM
Data refreshes hourly during market hours. Next update: 9:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HIND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 52 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |